The FDA granted traditional approval to selpercatinib for the treatment of advanced or metastatic RET-mutated medullary ...

Noah M. Merin, MD, PhD, assistant professor at Cedars-Sinai Medicine and medical director of the Hematology and Cellular ...

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

Missak Haigentz, MD, highlights some of the significant unmet needs for patients with small cell lung cancer.

A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated ...

CML is a complex disease and according to Mauro, decision-making often depends on the stage at diagnosis. He explains that it is crucial to carefully assess both the disease and the patient's overall ...

Camrelizumab increased the 3-year event-free survival rate vs standard of care from 77.3% to 86.9%, translating to a 44% ...

Binod Dhakal, MD, MS, discusses some of the challenges often seen in the myeloma space, particularly those with lenalidomide-refractory multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 ...

Panelists discuss how the NATALEE study at ESMO 2024 presented updates on primary, secondary, and exploratory endpoints for evaluating a new cancer treatment.

Panelists discuss how updates from KEYNOTE-522 at ESMO 2024 revealed important data on overall survival and event-free survival outcomes.